The AIM-FFR trial is a prospective, multi-center, open-label, randomized controlled, non-inferiority trial. The current trial will evaluate non-inferiority of MPFFR-guided PCI, compared with invasive FFR-guided PCI in patients with coronary artery disease.
Who can participate
Age range19 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Subject must be at least 19 years of age
✓. Eligible for coronary angiography and/or percutaneous coronary intervention.
✓. Coronary artery disease in one or more native major epicardial vessels or their branches with reference vessel diameter of at least 2.5mm and with visually assessed coronary stenosis in which the physiological severity of the lesion is questionable (typically 40-90% diameter stenosis).
✓. Subject who is able to understand risks, benefits and treatment alternatives and sign informed consent voluntarily.
Exclusion criteria
✕. Patients unable to provide informed consent
✕. Patients with known intolerance to aspirin, P2Y12 inhibitors, or components of drug-eluting stents and drug-coated balloons
✕. Patients with coronary artery bypass grafting
✕. Patients who have non-cardiac co-morbid conditions with life expectancy \<1 year
✕. Patients with cardiogenic shock or cardiac arrest
✕. Patients with severe left ventricular systolic dysfunction (ejection fraction \<30%)
✕. Patients with severe valvular heart disease requiring open heart surgery